CT and MRI marrow dosimetry identifies potential toxicity constraints for cervical cancer chemoradiotherapy

In 68 cervical cancer patients, pelvic marrow dose correlated with hematologic toxicity, supporting stricter exploratory constraints for 44 Gy in 20 fractions.

KEY POINTS

  • This pooled analysis included 68 patients with locally advanced cervical cancer from single-institution EMBRACE-II and HYPOCx-iRex cohorts. Patients received 45 Gy in 25 fractions without marrow sparing (EMBRACE-II, n=28), 45 Gy in 25 fractions with marrow sparing (CVRT, n=19), or 44 Gy in 20 fractions with marrow sparing (HYPO, n=21), alongside concurrent chemoradiotherapy and image-guided brachytherapy.
  • Two bone marrow delineation approaches were evaluated. CT-based marrow (BM_CT) included pelvic and lumbosacral bony structures within the treatment region, whereas MRI-based marrow (BM_MRI) used iso- to hypointense T1/T2 marrow as a surrogate for active hematopoietic tissue; the femora were excluded from the primary marrow volumes.
  • Acute grade ≥2 composite hematologic toxicity, excluding lymphopenia, occurred in 79% of EMBRACE-II, 68% of CVRT and 67% of HYPO patients (p=0.62). Grade ≥3 toxicity occurred in 18%, 11% and 24%, respectively (p=0.61), indicating no statistically significant difference between groups despite lower planned marrow exposure in the sparing cohorts.
  • Across the complete population, CT-based marrow dose showed significant associations with grade ≥3 hematologic toxicity. Probit-derived ED10 values were approximately V20Gy 74%, V25Gy 480 cc, V30Gy 360 cc and V35Gy 235 cc, where ED10 represented modeled dose-volume levels associated with a 10% toxicity probability.
  • In the 44 Gy/20-fraction subgroup, MRI-defined active marrow metrics were specifically associated with grade ≥2 hematologic toxicity, with ED10 values of V25Gy 39% and mean dose 24 Gy. The authors proposed more practically achievable hypofractionation objectives of BM_MRI V25Gy <45% and Dmean <25 Gy.
  • For broader clinical planning, the authors proposed CT-based marrow constraints of V20Gy <70%, V25Gy <450 cc, V30Gy <300 cc and V35Gy <200 cc. These were derived from the observed dose–toxicity relationships and suggested for incorporation into future prospective protocols, not validated as universal clinical safety limits.
  • Severe lymphopenia remained essentially universal despite marrow sparing: 67 of 68 patients developed grade ≥3 lymphopenia. The small pooled sample, heterogeneous fractionation, lack of PET-confirmed active marrow, and multiple exploratory dose-volume comparisons limit confidence in the proposed thresholds and their ability to reduce clinical hematologic events.

CLINICAL TAKEAWAY

CT-based pelvic marrow constraints may offer a practical planning strategy for conventional and hypofractionated cervical cancer chemoradiotherapy, while MRI-derived active marrow metrics may be particularly relevant for the 44 Gy/20-fraction schedule. However, the proposed thresholds should be treated as research planning objectives rather than established constraints, especially because the observed between-group differences in hematologic toxicity were not statistically significant.

SOURCE

Advances in Radiation Oncology

Browse more research Suggest a correction